Online inquiry

IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15506MR)

This product GTTS-WQ15506MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets FCGRT gene. The antibody can be applied in Myasthenia Gravis (MG) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ15506MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2807MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG-301
GTTS-WQ4098MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BI-204
GTTS-WQ11790MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MK-3222
GTTS-WQ5239MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CB 2679d
GTTS-WQ731MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AAB-001
GTTS-WQ4236MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BIIB031
GTTS-WQ5123MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CAN-04
GTTS-WQ5740MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CEA-IL-2v
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW